This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. Duo Hybrid has a distinct integrated design that combines multiple zones of differing mechanical properties into a single stent [3].
In-silico evaluation (computer simulated analysis in a virtual stroke model) has the potential to test and optimize large number of stent-retriever design variations in a relatively time and cost-effective manner. Gravity Medical Technology’s SuperNova Stent-retriever was the device under investigation.
In‐silico evaluation (computer simulated analysis in a virtual stroke model) has the potential to test and optimize large number of stent‐retriever design variations in a relatively time and cost‐effective manner. Further, new design concepts can be tested across multiple anatomical scenarios.
As an alternative therapeutic option, LVAD heart pumps have been implanted to help patients with end-stage heart failure sustain blood circulation in the body. However, there are shortcomings associated with LVAD implantation: complications include infection, bloodclotting (thrombosis), stroke and bleeding.
In addition, patients treated with CSL112 were 32% less likely to have a heart attack caused by a bloodclot in a stent (a tiny mesh tube inserted into an artery to prevent it from becoming blocked) at 90 days and 29% less likely at 180 days.
In addition, patients treated with CSL112 were 32% less likely to have a heart attack caused by a bloodclot in a stent (a tiny mesh tube inserted into an artery to prevent it from becoming blocked) at 90 days and 29% less likely at 180 days.
February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes. The label includes a “black box” warning for CV risk due to bloodclots.
These modifications contribute to improved blood flow, weight management and overall cardiovascular health. Antiplatelet medicines help to reduce the risk of bloodclots while statins help to lower blood cholesterol levels and stabilize plaque in the arteries.
This video is not for those patients who have already had a heart attack or a stroke or stents or bypasses or some other form of vascular event who are trying to prevent a further event by taking Aspirin. For those people there exists the Secondary Bank of Aspirin which I shall talk about in a later video.
Three coronary arteries supply blood to the heart. When one of these arteries becomes completely blocked by a bloodclot, it results in a heart attack, also known as MI (Myocardial infarction). Medical and Surgical Treatment in a Heart Attack An MI occurs when a bloodclot entirely obstructs a blood artery in the heart.
Aneurysms can form in any blood vessel, but they occur most commonly in the aorta (aortic aneurysm) which is the main blood vessel leaving the heart: Thoracic aortic aneurysm Abdominal aortic aneurysm Venous Diseases & BloodClots Varicose Veins: Bulging, swollen, purple, ropy veins seen just under your skin.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content